Curcumin ( DrugBank: Curcumin )

---

11 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	1
13	Multiple sclerosis/Neuromyelitis optica	1
46	Malignant rheumatoid arthritis	1
49	Systemic lupus erythematosus	1
67	Polycystic kidney disease	1
74	Prolactin secreting pituitary adenoma	1
94	Primary sclerosing cholangitis	1
96	Crohn disease	5
97	Ulcerative colitis	7
139	Congenital cerebral hypomyelination	1
299	Cystic fibrosis	2

2. Amyotrophic lateral sclerosis

---

Clinical trials : 624 /  Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04654689 (ClinicalTrials.gov)	November 20, 2021	13/11/2020	Impact of the Combined Treatment of Liposomed Polyphenols With G04CB02 on the ALS Patients	Impact of the Combined Treatment of Curcumin and Resveratrol Liposomed Polyphenols With G04CB02 on the Clinical Improvement of ALS Patients	Amyotrophic Lateral Sclerosis	Dietary Supplement: Liposomed polyphenols resveratrol and curcumin;Other: Placebo for liposomed resveratrol and curcumin;Dietary Supplement: Isocaloric Diet;Drug: G04CB02;Other: Placebo microcrystalline methylcellulose	Fundación Universidad Católica de Valencia San Vicente Mártir	NULL	Recruiting	18 Years	75 Years	All	60	Phase 2	Spain

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,342 /  Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01514370 (ClinicalTrials.gov)	April 30, 2012	17/1/2012	Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a	ProspeCtive Study to Evaluate Efficacy, Safety and tOlerability of Dietary supplemeNT of Curcumin (BCM95) in Subjects With Active Relapsing MultIple Sclerosis Treated With subcutaNeous Interferon Beta 1a 44 mcg Three Times a Week (TIW)	Multiple Sclerosis	Drug: IFN beta 1a 44 mcg TIW;Drug: Curcumin;Drug: Placebo	Merck KGaA, Darmstadt, Germany	Merck Serono S.P.A., Italy	Completed	18 Years	60 Years	All	80	Phase 2	Italy

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,325 /  Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00752154 (ClinicalTrials.gov)	January 2010	11/9/2008	Curcumin in Rheumatoid Arthritis	Curcumin in Rheumatoid Arthritis - ACross-Over Pilot Study	Rheumatoid Arthritis	Drug: Curcumin (Longvida™)	University of California, Los Angeles	NULL	Recruiting	18 Years	N/A	Both	40	Phase 0	United States

49. Systemic lupus erythematosus

---

Clinical trials : 946 /  Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03953261 (ClinicalTrials.gov)	September 1, 2019	14/5/2019	Effect of Curcumin on Systemic Lupus Erythematosus	Effect of Curcumin on Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: Curcumin supplement	Loma Linda University	NULL	Recruiting	18 Years	N/A	All	68	Phase 2	United States

67. Polycystic kidney disease

---

Clinical trials : 216 /  Drugs : 219 - (DrugBank : 50) / Drug target genes : 39 - Drug target pathways : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02494141 (ClinicalTrials.gov)	November 12, 2015	25/6/2015	Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD	Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD	Polycystic Kidney, Autosomal Dominant	Drug: Curcumin;Other: Placebo	University of Colorado, Denver	NULL	Completed	6 Years	25 Years	All	68	Phase 4	United States

74. Prolactin secreting pituitary adenoma

---

Clinical trials : 18 /  Drugs : 33 - (DrugBank : 10) / Drug target genes : 16 - Drug target pathways : 65

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01344291 (ClinicalTrials.gov)	July 2011	18/4/2011	Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients		Hyperprolactinoma	Drug: Curcumin	Mashhad University of Medical Sciences	NULL	Recruiting	20 Years	45 Years	Female	30	Phase 1	Iran, Islamic Republic of

94. Primary sclerosing cholangitis

---

Clinical trials : 142 /  Drugs : 113 - (DrugBank : 37) / Drug target genes : 19 - Drug target pathways : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02978339 (ClinicalTrials.gov)	June 9, 2017	22/11/2016	A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis (PSC)	An Open-Label Pilot Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis	Primary Sclerosing Cholangitis	Drug: Curcumin	John E. Eaton	EuroPharma, Inc.	Completed	18 Years	75 Years	All	15	Phase 1/Phase 2	United States

96. Crohn disease

---

Clinical trials : 2,400 /  Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04713631 (ClinicalTrials.gov)	January 2021	3/12/2020	Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease	Phase 2a Randomised Double-blind Placebo-controlled Trial to Assess Safety, Efficacy of Artesunate & Curcumin in Crohn's Disease Patients, Who Continue to Have Mild to Moderate Disease Activity on an Adequate Dose of Azathioprine	Crohn's Disease	Drug: Artesunate;Drug: Curcumin;Drug: Placebo A;Drug: Placebo C	Sanjay Gandhi Postgraduate Institute of Medical Sciences	St George's University of London, London, UK	Not yet recruiting	18 Years	65 Years	All	40	Phase 2	India
2	NCT02255370 (ClinicalTrials.gov)	December 2014	19/9/2014	Curcumin Associated With Thiopurin in the Prevention of Post-op Recurrence in Crohn Disease	Controlled, Randomized, Double Blind Study, Comparing Curcumin to Thiopurines in the Prevention of Post-op Recurrence in Crohn Disease	Crohn's Disease	Drug: Curcumin	University Hospital, Clermont-Ferrand	3i nature;Naturopôle Nutrition santé	Completed	18 Years	N/A	All	61	Phase 3	France
3	EUCTR2014-000261-51-FR (EUCTR)	04/11/2014	28/08/2015	Randomized, controlled, double bind study, comparing curcumin to placebo, associated with thiopurines, in the the prevention of post-operative Crohn's desease relapse	POPCUR : a randomized, controlled, double bind study, comparing curcuma to placebo, associated with thiopurines, in the prevention of post-operative Crohn's disease recurrence - POPCUR	Crohn's Disease MedDRA version: 18.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Curcuma Other descriptive name: CURCUMA LONGA RHIZOMA	CHU de Clermont-Ferrand	NULL	Not Recruiting			Female: yes Male: yes	122	Phase 3	France
4	JPRN-UMIN000015770	2014/09/01	01/12/2014	Randomized double-blind multicenter study for anti-inflammatory effects of highly bioavailable curcumin on Crohn's disease.	Randomized double-blind multicenter study for anti-inflammatory effects of highly bioavailable curcumin on Crohn's disease. - Exploratory study for effects of highly bioavailable curcumin on Crohn's disease.	Crohn's disease (180 <= CDAI < 450)CDAI: Crohn's disease Activity Index	Standard therapy for Crohn's disease (Pentasa 3 g/day) Patients take curcumin or placebo	Hamamatsu South Hospital, Centre for Gastroenterology and Inflammatory Bowel Disease Research	NULL	Complete: follow-up complete	20years-old	70years-old	Male and Female	30	Not selected	Japan
5	NCT00889161 (ClinicalTrials.gov)	May 2009	24/4/2009	Curcumin in Pediatric Inflammatory Bowel Disease	Curcumin in Pediatric Inflammatory Bowel Disease: A Forced Dose Titration Study	Inflammatory Bowel Disease;Ulcerative Colitis;Crohn's Disease	Drug: Curcumin	Seattle Children's Hospital	NULL	Completed	8 Years	18 Years	Both	11	Phase 1	United States

Back to top

97. Ulcerative colitis

---

Clinical trials : 2,527 /  Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02277223 (ClinicalTrials.gov)	March 1, 2020	25/10/2014	Curcumin in Pediatric Ulcerative Colitis	Curcumin for Induction and Maintenance Therapy in Pediatric Ulcerative Colitis	Ulcerative Colitis	Dietary Supplement: Curcumin;Drug: Placebo	Schneider Children's Medical Center, Israel	NULL	Withdrawn	6 Years	18 Years	All	0	Phase 3	Israel
2	ChiCTR1900022243	2019-04-01	2019-03-31	Effect of curcumin combined with probiotics on prevention and treatment in ileal pouchitis after operation of ulcerative colitis.	Effect of curcumin combined with probiotics on prevention and treatment in ileal pouchitis after operation of ulcerative colitis.	ileal pouchitis after operation of ulcerative colitis	Experimental group:Curcumin+Probiotics;Control group:Probiotics;	Tianjin Medical University General Hospital	NULL	Recruiting			Both	Experimental group:20;Control group:10;		China
3	NCT03122613 (ClinicalTrials.gov)	June 19, 2017	7/4/2017	Curcumin for Prevention of Relapse in Patients With Ulcerative Colitis	A Double-blind, Randomized, Placebo-Controlled Trial of Curcumin Versus Placebo for Prevention of Relapse in Patients With Ulcerative Colitis	Ulcerative Colitis in Remission	Dietary Supplement: Curcumin;Drug: Placebo	Chinese University of Hong Kong	NULL	Recruiting	18 Years	N/A	All	172	N/A	Hong Kong
4	NCT02683733 (ClinicalTrials.gov)	February 2016	10/2/2016	Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative Colitis	The Efficacy and Tolerability of Bio-enhanced Curcumin (Diferuloylmethane) in the Induction of Remission in Patients With Mild to Moderate Ulcerative Colitis	Ulcerative Colitis	Dietary Supplement: Bio-enhanced Curcumin Soft Gelatin Capsule;Drug: 5-Aminosalicylic acid	Asian Institute of Gastroenterology, India	NULL	Recruiting	18 Years	70 Years	Both	50	Phase 3	India
5	NCT02683759 (ClinicalTrials.gov)	February 2016	10/2/2016	Bio-enhanced Curcumin as an Add-on Treatment in Maintaining Remission of Ulcerative Colitis	The Efficacy and Tolerability of Bio-Enhanced Curcumin in Maintaining Remission in Patients With Ulcerative Colitis	Ulcerative Colitis	Dietary Supplement: Bio-enhanced Curcumin Soft Gelatin Capsule;Drug: 5-Aminosalicyclic acid	Asian Institute of Gastroenterology, India	NULL	Recruiting	18 Years	70 Years	Both	50	Phase 3	India
6	NCT01320436 (ClinicalTrials.gov)	July 2011	21/3/2011	Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis	Randomized, Double-blind, Placebo-controlled Study to Evaluated the Efficacy of Combining Curcumin+5ASA Medication Versus 5ASA Medication Alone on Active Mild to Moderate Ulcerative Colitis Patients	Ulcerative Colitis	Dietary Supplement: Curcumin;Drug: 5-aminosalicylic acid	Sheba Medical Center	NULL	Completed	18 Years	70 Years	Both	50	Phase 3	Israel
7	NCT00889161 (ClinicalTrials.gov)	May 2009	24/4/2009	Curcumin in Pediatric Inflammatory Bowel Disease	Curcumin in Pediatric Inflammatory Bowel Disease: A Forced Dose Titration Study	Inflammatory Bowel Disease;Ulcerative Colitis;Crohn's Disease	Drug: Curcumin	Seattle Children's Hospital	NULL	Completed	8 Years	18 Years	Both	11	Phase 1	United States

Back to top

139. Congenital cerebral hypomyelination

---

Clinical trials : 10 /  Drugs : 7 - (DrugBank : 2) / Drug target genes : 2 - Drug target pathways : 2

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs031180348	01/04/2018	18/03/2019	Effectiveness of Curcumin for PMD	Effectiveness of Curcumin (an active integrant in turmeric) for Pelizaeus-Merzbacher disease: an exploratory study - Effectiveness of Curcumin for PMD	Pelizaeus-Merzbacher disease Neurology/Pediatrics;D020371	Low dose curcumin (1mg/kg/day, oral, once a day) for 2 months followed by high dose curcumin (4mg/kg/day, oral, once a day) for 10 months.	Inoue Ken	NULL	Complete	5age	20age	Male	10	N/A	Japan

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-000817-30-NL (EUCTR)	14/08/2014	22/05/2014	Comparing the effect of curcumin and genistein to treatment with Ivacaftor in CF patients with a class III mutation	Comparing the effect of curcumin and genistein to treatment with Ivacaftor in CF patients with a class III mutation - TICTAC-study	Cystic Fibrosis;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Ivacaftor/Kalydeco Product Name: Curcuma Longa Extract cpl formaat 00 23,2 x 8,5 mm 723 mg INN or Proposed INN: curcumin Other descriptive name: CURCUMIN Product Name: Genisteine Plus 150 mg cpl formaat 1 18,7 x 6,4 mm 438 mg INN or Proposed INN: genistein Other descriptive name: GENISTEIN	University Medical Centre Utrecht	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	Netherlands
2	NCT00219882 (ClinicalTrials.gov)	April 2005	16/9/2005	Safety Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis	A Phase I Safety and Dose Finding Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis Who Are Homozygous for Delta F508 Cystic Fibrosis Transmembrane Conductance Regulator (?F508 CFTR) Mutation	Cystic Fibrosis	Drug: standardized turmeric root extract	Ramsey, Bonnie, MD	Seer Pharmaceuticals;CF Therapeutics Development Network Coordinating Center;Cystic Fibrosis Foundation Therapeutics	Completed	18 Years	40 Years	Both	11	Phase 1	United States

Back to top